Organization | Seth Gordhandas Sunderdas Medical College

Seth Gordhandas Sunderdas Medical College Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Mumbai India (1926)

Organization Overview

First Clinical Trial

2007

NCT00525408

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2012

Timeline

NOW

Alternative names

GSMC and KEM Hospital | Seth GSMC and KEM hospital, Mumbai | Seth GS Medical College and KEM Hospital | Seth G S Medical College & K E M Hospital | SEth G S Medical College & KEM Hospital

Active Ingredients

Drugs in Phase 3 Trials (2)

cabergoline (dostinex) (1 trial)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135) (1 trial)

Drugs in Phase 2 Trials (5)

allogeneic adipose derived mesenchymal stem cell (1 trial)

bacille calmette-guerin (1 trial)

docetaxel (taxotere) (1 trial)

immuvac (1 trial)

mycobacterium w vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

ACTH-Secreting Pituitary Adenoma (Phase 3)

Adenoma (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Meningitis (Phase 3)

Meningitis, Bacterial (Phase 3)

Mycobacterium Infections (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pituitary ACTH Hypersecretion (Phase 3)

Pituitary Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 7